Literature DB >> 25648219

Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma.

Shinya Neri1,2,3, Genichiro Ishii1, Hiroko Hashimoto1, Takeshi Kuwata1, Kanji Nagai2, Hiroshi Date3, Atsushi Ochiai1.   

Abstract

Cancer-associated fibroblasts (CAFs) communicate with cancer cells and play important roles in cancer invasion. We previously reported that local invasion of cancer cells was frequently observed in lung adenocarcinoma patients with podoplanin (PDPN)-expressing CAFs. However, the underlying mechanisms of this phenomenon have remained unclear. In this study, we established a novel collagen invasion assay model in which cancer cells and CAFs were cocultured; we analyzed the mechanisms governing how cancer cell invasion was promoted by PDPN(+)CAFs. By observing the dynamic movement of both CAFs and cancer cells in the collagen matrix, we found that PDPN(+)CAFs invaded the matrix to a greater extent, with more cancer cells invading within the "tracks" created by the CAFs, compared with control CAFs. The knockdown of PDPN in CAFs decreased the invasion of both the CAFs and the cancer cells. PDPN(+)CAFs displayed a higher RhoA activity and treatment with a ROCK inhibitor cancelled the increased invasion ability of PDPN(+)CAFs and subsequently decreased the number of invaded cancer cells. After intravenous injection in the mouse tail vein, PDPN(+)CAFs invaded and promoted cancer cell invasion into the lung parenchyma, compared with control CAFs. Among the patients with lung adenocarcinoma, we observed some cases with PDPN(+)CAFs at the invasive front of the tumor. These cases predominantly exhibited pleural invasion of cancer cells, known as pathological invasiveness. Our results indicated that PDPN(+)CAFs were tumor-promoting CAFs that lead and enhance the local invasion of cancer cells, suggesting that the invasion activity of CAFs themselves could be rate-determining for cancer cell invasion.
© 2015 UICC.

Entities:  

Keywords:  cancer invasion; cancer-associated fibroblasts; podoplanin; tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 25648219     DOI: 10.1002/ijc.29464

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Interaction between cancer cells and cancer-associated fibroblasts after cisplatin treatment promotes cancer cell regrowth.

Authors:  Shoshi Hisamitsu; Tomoyuki Miyashita; Hiroko Hashimoto; Shinya Neri; Masato Sugano; Hiroshi Nakamura; Shota Yamazaki; Atsushi Ochiai; Koichi Goto; Masahiro Tsuboi; Genichiro Ishii
Journal:  Hum Cell       Date:  2019-08-22       Impact factor: 4.174

2.  Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.

Authors:  Shoko Nakasone; Sachiyo Mimaki; Tomohiro Ichikawa; Keiju Aokage; Tomohiro Miyoshi; Masato Sugano; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Masahiro Tsuboi; Koichi Goto; Katsuya Tsuchihara; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-06       Impact factor: 4.553

3.  A novel method to generate single-cell-derived cancer-associated fibroblast clones.

Authors:  Hiroko Hashimoto; Yoshitaka Suda; Tomoyuki Miyashita; Atsushi Ochiai; Masahiro Tsuboi; Kenkichi Masutomi; Tohru Kiyono; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-31       Impact factor: 4.553

Review 4.  The emerging roles of exosomes in tumor-stroma interaction.

Authors:  Hailong Fu; Huan Yang; Xu Zhang; Wenrong Xu
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-17       Impact factor: 4.553

5.  Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts.

Authors:  Shinya Neri; Hiroko Hashimoto; Hiroaki Kii; Hirotada Watanabe; Kenkichi Masutomi; Takeshi Kuwata; Hiroshi Date; Masahiro Tsuboi; Koichi Goto; Atsushi Ochiai; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-15       Impact factor: 4.553

6.  The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.

Authors:  Masaki Goto; Masahito Naito; Koichi Saruwatari; Kakeru Hisakane; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Shogo Nomura; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Kohei Yokoi; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

7.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

8.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.

Authors:  Sunny Z Wu; Daniel L Roden; Chenfei Wang; Holly Holliday; Kate Harvey; Aurélie S Cazet; Kendelle J Murphy; Brooke Pereira; Ghamdan Al-Eryani; Nenad Bartonicek; Rui Hou; James R Torpy; Simon Junankar; Chia-Ling Chan; Chuan En Lam; Mun N Hui; Laurence Gluch; Jane Beith; Andrew Parker; Elizabeth Robbins; Davendra Segara; Cindy Mak; Caroline Cooper; Sanjay Warrier; Alistair Forrest; Joseph Powell; Sandra O'Toole; Thomas R Cox; Paul Timpson; Elgene Lim; X Shirley Liu; Alexander Swarbrick
Journal:  EMBO J       Date:  2020-08-13       Impact factor: 11.598

Review 10.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.